-
Mashup Score: 3
En el campo de la oncología en Puerto Rico, diversos nombres resuenan con respeto y admiración, así como el Dr. Luis Delgado Mateu, director médico del Hospital Oncológico de Puerto Rico y especialista en hematología y oncología. En BeHealth tuvimos el honor de conversar con él sobre su trayectoria, desafíos y la realidad de la oncología en la isla. Al hablar de su equipo, el Dr. Delgado se llena de orgullo: «Me siento muy afortunado de formar parte de este equipo, que es más que un grupo de colegas, es una verdadera familia. Hemos trabajado juntos durante muchos años; somos un equipo comprometido, no solo nosotros los médicos, sino todo el personal que nos brinda apoyo día a día”. Los retos de la dirección y el sistema de salud en Puerto Rico La dirección de un hospital no está exenta de desafíos, especialmente en un contexto de crisis hospitalaria que afecta tanto a hospitales privados como al sistema público en Puerto Rico. «La dirección enfrenta sin duda sus retos, pero contar con
Source: behealthoncologia.comCategories: General Medicine NewsTweet
-
Mashup Score: 44
There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile. Joining Dr. Jacob Sands to talk more about these findings and their implications are Drs. Elaine Shum and Estelamari Rodriguez. Dr. Shum is an Assistant Professor in the Department of Medicine at NYU Grossman School of Medicine, and Dr. Rodriguez is an Associate Director of Community Outreach, Thoracic Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Health System.
Source: reachmd.comCategories: General Medicine NewsTweet-
So much fun recording this educational video with @sands_jacob @DanaFarber and @elaineshum @nyulangone on Evaluating #DatoDXd for #EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis https://t.co/bA2wjXkN27 via @ReachMD @EGFRResisters https://t.co/PeqijO3Tph
-
-
Mashup Score: 5
PURPOSETo evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (ex20ins) mutations.METHODS…
Source: ascopubs.orgCategories: General Medicine NewsTweet-
#ASCO25: Oral Abs 8503 #REZILIENT-1 #Zipalertinib 💊#EGFR20ins 🫁NSCLCin after chemo/ amivantamab 🎙️@HelenaYu923 @MSKCC_OncoNotes 🔹N=176 🔹ORR 35% (40% in prior Amivantamab group) 🔹mPFS 9.5 mos ⬆️ CNS efficacy 📝 Publication: https://t.co/fL44JpXbNY #lcsm @EGFRResisters https://t.co/cVaHnVVe6k
-
-
Mashup Score: 0Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST - 20 day(s) ago
PURPOSETaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1+ non–small cell lung cancer.METHODSTRUST-I and …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
https://t.co/UHE46Q56MZ
-
-
Mashup Score: 0
PURPOSEAdjuvant osimertinib is standard-of-care for patients with resected epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes.METHODSIn this randomized, …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
📝Publication: https://t.co/gIBUogIqEH
-
-
Mashup Score: 0
IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adverse events. Lurbinectedin plus atezolizumab represents a novel therapeutic option for first-line maintenance treatment in this setting.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
✍️ Publication: https://t.co/7RbxW5LL6N
-
-
Mashup Score: 2
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 tri…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
https://t.co/KpcsgJX8rF
-
-
Mashup Score: 3997
IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adverse events. Lurbinectedin plus atezolizumab represents a novel therapeutic option for first-line maintenance treatment in this setting.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
✍️ Publication: https://t.co/7RbxW5LL6N
-
-
Mashup Score: 5
IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adverse events. Lurbinectedin plus atezolizumab represents a novel therapeutic option for first-line maintenance treatment in this setting.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
✍️ Publication: https://t.co/7RbxW5LL6N
-
-
Mashup Score: 0
PURPOSEAdjuvant osimertinib is standard-of-care for patients with resected epidermal growth factor receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes.METHODSIn this randomized, …
Source: ascopubs.orgCategories: General Medicine NewsTweet-
📝Publication: https://t.co/gIBUogIqEH
-
https://t.co/RR9n37vWhN